Key result
Intravenous iron administration in patients with heart failure with reduced ejection fraction and iron deficiency reduces symptoms, improves quality of life and exercise tolerance, and reduces hospital admissions for heart failure.
Why the study?
Iron deficiency in heart failure is common and associated with worse prognosis, prompting investigation into whether intravenous iron administration affects quality of life, hospital admissions, and cardiovascular deaths.
Does intravenous iron administration improve quality of life and reduce hospital admissions and deaths in patients with heart failure with reduced ejection fraction and iron deficiency?
Does intravenous iron administration improve quality of life and reduce hospital admissions and deaths in patients with heart failure with reduced ejection fraction and iron deficiency?
Intravenous iron administration in patients with HFrEF and iron deficiency improves symptoms, quality of life, and reduces heart failure hospitalizations.
Supports IV iron for symptom relief and fewer HF admissions in iron-deficient HFrEF; leaves open mortality effects pending prospective trials.
Introduction and Purpose Iron deficiency in patients with heart failure is a common problem of which they are often unaware. It is associated with a worse prognosis compared to patients suffering with heart failure without iron deficiency. An important point in the diagnosis in patients with heart failure would be the determination of iron in the blood, in order to catch patients eligible for intravenous iron administration. The aim of the study was to investigate whether intravenous iron administration could affect quality of life in these patients and further reduce hospital admissions for heart failure exacerbations and deaths caused by cardiovascular events. Material and Methods A comprehensive literature review was conducted using the PubMed and Google Scholar database. We used the key words: ‘heart failure’ in combination with medical terms referring to iron status or its therapeutic use , “iron deficiency”, “intravenous iron”, “intravenous ferric carboxymaltose”, “intravenous ferric derisomaltose” in various combinations. Results and conclusions Intravenous iron administration in patient with heart failure with reduced ejection fraction and iron deficiency reduces symptoms, improves quality of life, exercise tolerance and reduces hospital admissions for heart failure. It is very important to actively look for iron deficiency in patients with heart failure, and then patients who meet the criteria should be provided with an intravenous iron administration.
No takes yet. Share an insight, caveat, or question.
Dąbek et al. (2024) conducted a review in Heart failure with reduced ejection fraction and iron deficiency. Intravenous iron (ferric carboxymaltose, ferric derisomaltose) vs. Placebo or oral iron was evaluated on Symptoms, quality of life, exercise tolerance, and hospital admissions for heart failure. Intravenous iron administration in patients with heart failure with reduced ejection fraction and iron deficiency reduces symptoms, improves quality of life and exercise tolerance, and reduces hospital admissions for heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: